Oral tolerance: a new tool for the treatment of gastrointestinal inflammatory disorders and liver-directed gene therapy.

Oral tolerance is a method of downregulating an immune response by feeding antigens. The use of oral tolerance toward adenoviruses and colitis-extracted proteins for long term gene therapy and alleviation of experimental colitis, and the mechanisms of tolerance induction are presented. Adenoviruses are efficient vectors in liver-directed gene therapy; however, the antiviral immune response precludes the ability to achieve long term gene expression and prohibits the ability to reinject the recombinant virus. Oral tolerance induction via feeding of viral-extracted proteins prevented the antiadenoviral humoral and cellular immune responses, thus enabling long term gene therapy using these viruses. Moreover, pre-existing immune response to the virus was overcome by tolerance induction, enabling prolonged gene expression in a presensitized host. Inflammatory bowel diseases are immune-mediated disorders where an imbalance between proinflammatory (T helper cell type 1) and anti-inflammatory (T helper cell type 2) cytokines are thought to play a role in the pathogenesis. In the experimental colitis model, the feeding of colitis-extracted proteins downregulated the anticolon immune response. Tolerance induction toward colitis-extracted proteins ameliorated colonic inflammation as shown by decreased diarrhea and reduction of colonic ulcerations, intestinal and peritoneal adhesions, wall thickness and edema. Histological parameters for colitis were markedly improved in tolerized animals. In both models, tolerized animals developed an increase in transforming growth factor-beta, interleukin-4 and interleukin-10, and a decrease in the mRNA of interferon-gamma lymphocytes and serum levels. Adoptive transfer of tolerized lymphocytes enabled the transfer of tolerance toward adenoviruses and colon-extracted proteins. Thus, oral tolerance induces suppressor lymphocytes that mediate immune response downregulation by induction of a shift from a proinflammatory T helper cell type 1 to an anti-inflammatory T helper cell type 2 immune response.

[1]  M. Ott,et al.  Oral tolerization to adenoviral proteins permits repeated adenovirus‐mediated gene therapy in rats with pre‐existing immunity to adenoviruses , 1998, Hepatology.

[2]  N. Chowdhury,et al.  Treatment of experimental colitis through induction of oral tolerance towards colitis-extracted proteins , 1998 .

[3]  N. Chowdhury,et al.  A critical role of the liver in inducing oral tolerance to adenoviral vectors for long-term gene therapy , 1998 .

[4]  J. Roy-Chowdhury,et al.  Transient immunosuppression with FK506 permits long‐term expression of therapeutic genes introduced into the liver using recombinant adenoviruses in the rat , 1997, Hepatology.

[5]  C. Elson,et al.  Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. , 1997, Gastroenterology.

[6]  C. Kurts,et al.  Class I–restricted Cross-Presentation of Exogenous Self-Antigens Leads to Deletion of Autoreactive CD8+ T Cells , 1997, The Journal of experimental medicine.

[7]  H. Weiner.  Oral tolerance: immune mechanisms and treatment of autoimmune diseases. , 1997, Immunology today.

[8]  S. Lewis,et al.  Interleukin 10 prevents cytokine-induced disruption of T84 monolayer barrier integrity and limits chloride secretion. , 1997, Gastroenterology.

[9]  S. Lundin,et al.  Oral tolerance in experimental animals. , 1997, International archives of allergy and immunology.

[10]  G. Droguett,et al.  Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[11]  G. Droguett,et al.  Oral tolerization to adenoviral antigens permits long-term gene expression using recombinant adenoviral vectors. , 1997, The Journal of clinical investigation.

[12]  N. Vaz,et al.  Indirect Effects of Oral Tolerance Cannot be Ascribed to Bystander Suppression , 1997, Scandinavian journal of immunology.

[13]  T. Yoshida,et al.  The oral administration of low-dose antigen induces activation followed by tolerization, while high-dose antigen induces tolerance without activation. , 1997, Clinical immunology and immunopathology.

[14]  B. Ludviksson,et al.  Reciprocal IFN-γ and TGF-β responses regulate the occurrence of mucosal inflammation , 1997 .

[15]  W. Heath,et al.  Induction of Autoimmune Diabetes by Oral Administration of Autoantigen , 1996, Science.

[16]  M. Horwitz,et al.  Induction of central tolerance by intrathymic inoculation of adenoviral antigens into the host thymus permits long-term gene therapy in Gunn rats. , 1996, The Journal of clinical investigation.

[17]  M. V. von Herrath,et al.  Oral insulin treatment suppresses virus-induced antigen-specific destruction of beta cells and prevents autoimmune diabetes in transgenic mice. , 1996, The Journal of clinical investigation.

[18]  W. Strober,et al.  High dose oral tolerance in ovalbumin TCR-transgenic mice: systemic neutralization of IL-12 augments TGF-beta secretion and T cell apoptosis. , 1996, Journal of immunology.

[19]  M. Neurath,et al.  Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance , 1996, The Journal of experimental medicine.

[20]  S. Tonegawa,et al.  Cytokine imbalance and autoantibody production in T cell receptor-alpha mutant mice with inflammatory bowel disease , 1996, The Journal of experimental medicine.

[21]  H. Weiner,et al.  Suppression of insulitis in non-obese diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, transforming growth factor-beta, and prostaglandin-E. , 1995, The American journal of pathology.

[22]  C. Whitacre,et al.  Exquisite peptide specificity of oral tolerance in experimental autoimmune encephalomyelitis. , 1995, Journal of immunology.

[23]  M. Perricaudet,et al.  The constitutive expression of the immunomodulatory gp19k protein in E1-, E3- adenoviral vectors strongly reduces the host cytotoxic T cell response against the vector. , 1995, Gene therapy.

[24]  H. Ertl,et al.  Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses , 1995, Journal of virology.

[25]  N. Sarvetnick,et al.  Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[26]  D. Rimm,et al.  Autoantibodies specific for villin found in patients with colon cancer and other colitides , 1995, Digestive diseases and sciences.

[27]  C. Elson,et al.  Oral tolerance in humans. T cell but not B cell tolerance after antigen feeding. , 1994, Journal of immunology.

[28]  F. Graham,et al.  Packaging capacity and stability of human adenovirus type 5 vectors , 1993, Journal of virology.

[29]  H. Weiner,et al.  Effects of oral administration of type II collagen on rheumatoid arthritis. , 1993, Science.

[30]  H. Weiner,et al.  Oral, but not intravenous, alloantigen prevents accelerated allograft rejection by selective intragraft Th2 cell activation. , 1993, Transplantation.

[31]  H. Weiner,et al.  Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. , 1993, Science.

[32]  D. Kioussis,et al.  "Infectious" transplantation tolerance , 1993, Science.

[33]  S. Thorgeirsson,et al.  Adenovirus–mediated in vivo gene transfer and expression in normal rat liver , 1992, Nature Genetics.

[34]  K. Das,et al.  Isolation and characterization of a colonic autoantigen specifically recognized by colon tissue-bound immunoglobulin G from idiopathic ulcerative colitis. , 1985, The Journal of clinical investigation.

[35]  S. Fraenkel,et al.  Elevated numbers of peripheral T cells in inflammatory bowel diseases displaying T9 antigen and Fc alpha receptors. , 1985, Clinical and experimental immunology.

[36]  P. Novikoff,et al.  Distribution of UDPglucuronosyltransferase in rat tissue. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Alfred D. Eaton,et al.  Oral tolerance. , 2000, American journal of respiratory and critical care medicine.

[38]  P. Bosma,et al.  Jaundice and disorders of bilirubin metabolism , 1998 .

[39]  P. Matzinger.  Tolerance, danger, and the extended family. , 1994, Annual review of immunology.

[40]  F. Graham,et al.  Manipulation of adenovirus vectors. , 1991, Methods in molecular biology.